Key Takeaways
- Revenue up 17% YoY, margin squeezed: Consolidated revenue reached Rs. 2,343 crores, but EBITDA margin fell ~3-4% sequentially to 40% as raw material and energy costs spiked sharply.
- Cost inflation is the quarter's story: Solvent prices rose 30-100%, lithium 100-200%, coal ~30%, and power costs nearly doubled; management calls the pressure temporary and expects a return to normal in 1-2 years.
- Three growth engines are now yielding: Contrast media, sartans, and expanded generic capacities are all patent-expired and will start contributing as qualifications complete, without waiting for future patent cliffs.
- The big pharma value proposition is proven: Management's central claim is that Divi's alone can take an NCE from discovery to commercial supply with global regulatory clearance within 6 months, a capability now driving a pipeline of new molecule opportunities.
- What to watch next quarter: Progress on raw material cost pass-through negotiations, the pace of customer qualifications on the three yielding growth engines, and any land handover news from the Andhra Pradesh government for Kakinada.
Margin & Cost Environment
- Raw material spike: Solvent costs rose 30-50% with some doubling; lithium, a key input, rose 100-200%. Energy costs also jumped: coal up ~30%, grid power from ~Rs. 6 to Rs. 8+/unit, and generator power from Rs. 30-40 to Rs. 70-80/unit. Process efficiency and productivity remained unchanged, so the entire margin compression is input-cost driven.
- Cost pass-through is partial and slow: The company has convinced some customers to absorb raw material increases, especially for widely-known items like lithium. For solvents and fumes, negotiations take longer. Long-term contracts include a clause allowing discussion if costs rise more than 10%, and since most increases occurred in the last 3-6 months, talks are still ongoing.
- Costing strategy shifted: In the past, Divi's played safe by stocking material or locking prices into contracts, which gave slightly better costing. That buffer was absent in Q1. By August, costs were seeing a little better pricing but remain volatile and well above levels from two years ago.
- Solvent recovery as a margin lever: The company is deploying membrane technologies to recover and reuse high-cost solvents like tetrahydrofuran and acetonitrile where moisture content is critical, something not done 1-2 years ago. This backward integration benefit has already started contributing.
- No one-offs in other expenses: The only contributor to elevated other expenses is the fast-track project spend over the last 1-1.5 years; there are no exceptional items this quarter.
Dr. Murali K. Divi: "I expect that these unstable times of higher raw materials or a little bit effect on the margins is going to be temporary and we should be able to go back to where we were in the next 1-2 years."
Growth Engines & Capacity
- Three engines yielding now: Contrast media, sartans, and generics where capacity was increased are all patent-expired. They will start contributing as and when customer qualifications complete, without waiting for future patent expiries.
- Contrast media as a big growth engine: Capacity has been increased for some contrast media, DMFs filed as required, and process stabilization plus qualifications for other contrast media are underway. Management sees this as a big growth engine in the coming 2 years, with a strong competitive position built on an efficient iodine recovery and reuse system.
- Contrast media contract upside: A previously announced contract with one big pharma is completing validation and will move to commercial production without gap. Discussions are underway for a possible 2x upside on that contract.
- Sartans opportunity: Old generic sartans may face renewed problems with nitrosamine or azido impurities, creating more opportunities for Divi's, which is already commercializing them.
- Generic capacity step-up: Generic capacities have been increased and some qualifications completed; an increase in generic compound sales is expected. The process of validation, DMF submission, customer qualification, trial orders, and annual contracts started 1-2 years ago. Real volume will be visible after 2 years, but some income will come meanwhile as approvals arrive.
- Newer generics are high-value: Newer generic launches will not occupy a lot of capacity; they are high-priced, medium-volume products that will likely produce more margin and more value than legacy generics.
- Capacity headroom: Current available capacity stands at 17% on a huge volume base, meaning the company can accommodate many products or projects. Two new SEZ buildings under semi-construction could take that to 20%, depending on projects and equipment sizing.
- Capex outlook: Beyond Kakinada, management does not see more than Rs. 500-600 crores of further capex, directed at new technologies: photochemistry, flow chemistry, peptide chemistry, and high-potency antibody conjugated drugs, required for the next 3-4 years.
Dr. Murali K. Divi: "I love all the growth engines, because some of the growth engines give me a lot of stability, some of the growth engines grow like rockets."
Custom Synthesis & Big Pharma Positioning
- The NCE speed claim: Management's central competitive assertion is that Divi's alone can take a new chemical entity from discovery to commercial supply with all regulatory clearances within 6 months, a capability demonstrated during COVID and now driving a pipeline of new molecule opportunities from big pharma.
- Big pharma outsourcing tailwind: Big pharma companies have very little API manufacturing capacity of their own. For any molecule of large volume, COVID or non-COVID, that needs outsourcing and quick launch, Divi's proven track record gives it more opportunity than competitors.
- Post-patent custom synthesis is sticky: On patent expiry, the company does not lose all products or profitability. The patent holder's demand may drop from 100 to 70 or 80, but they still try to give more products into the basket. Divi's continues to enjoy premium pricing because the cost of API in a big pharma dosage form is not like a generic compound. Some big pharmas retain 90% of demand even after patent expiry because of critical impurity profiles that generics may take time to achieve, and in neurological medicines, patients do not want to change brands.
- Mix stays balanced: The product mix stands at 47% Generics, 53% Custom Synthesis. Management's objective is to keep them balanced at 50-50; variations are due to the lumpiness of large custom synthesis projects.
- Customer concentration to ease: Going forward, the business will be more diversified and will return to its historical pattern. The six growth engines, excluding regular generics, will bring stability so the company is not dependent on just 1 or 5 products.
Dr. Murali K. Divi: "If there is an NCE, if there is a large volume required, a company like Divi's only can do from NCE to launch commercial supply within 6 months and meet the whole world demand. That is what we have established in the world, which nobody has done in the past."
Export Mix & Supply Chain
- US share of exports surged: The US share of exports rose from 24% to 44% in FY22, while Europe fell from 47% to 33%. Management cautions against drawing conclusions: the mix depends on where big pharma customers have formulation capacity.
- Import dependency edged up: Import dependency increased from 44% to 46% in FY22 due to geopolitical tensions and logistical challenges. The company has tried to reduce dependency on China over 7 years by encouraging domestic manufacturers and doing backward integration, but China still holds the largest capacities in basic chemicals and dependency is not totally gone.
- COVID-related products wound down: The company developed several COVID-related products over 3-4 years. Demand for many, including Favipiravir and HCQ, either fell or was not there beyond a few months, and the company slowly stopped all of them.
- Molnupiravir status: All orders received have been completed; the company is awaiting and discussing further orders.
Nutraceuticals & Carotenoids
- Nutraceutical business grew: Revenue reached Rs. 186 crores, up from Rs. 138 crores YoY.
- Carotenoid sales jumped: After completing a 100% capacity expansion, sales jumped and the jump is expected to continue with further growth ahead.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin floor | Maintain 40% EBITDA margin including other income | Ongoing; "always" |
| Margin recovery | Return to pre-inflation margin levels as raw material and geopolitical conditions normalize | Next 1-2 years |
| Generic volume ramp | Real volume from capacity expansions and DMF filings to materialize after customer qualifications complete | After 2 years, with some income sooner |
| Contrast media growth | Big growth engine contribution from capacity additions and qualifications | Coming 2 years |
| Contrast media contract upside | Possible 2x upside on existing big pharma contrast media contract | Under discussion |
| Capex (ex-Kakinada) | Rs. 500-600 crores for new technology capabilities (photochemistry, flow chemistry, peptides, ADCs) | Next 3-4 years |
| Kakinada capex | Start with ~Rs. 1,000 crores, invest as project progresses | Conditional on land handover by Andhra Pradesh government |
| Kakinada project sequencing | Kakinada taken up first; Krishnapatnam only after Kakinada completes | No date; awaiting land |
| Capacity headroom | Move from 17% to ~20% available capacity via two new SEZ buildings | As buildings complete |
| Patent expiry opportunity | Capture share of ~$20 billion worth of APIs going off-patent; DMFs submitted or under preparation | 2023-2025 patent cliff window |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Consolidated total revenue | ₹2,343 cr, growth of 17% YoY |
| Constant currency growth | 9% YoY |
| Profit before tax | ₹851 cr |
| Profit after tax | ₹702 cr |
| EBITDA margin | 37.6% (40% including other income), management expects to maintain 40% |
| Exports share | 90% of total revenue |
| Exports to regulated markets | 74% of total revenue |
| Product mix (Generics vs Custom Synthesis) | 47% / 53% |
| Nutraceutical business revenue | ₹186 cr, up from ₹138 cr in Q1 FY22 |
| ForEx gain | ₹56 cr |
| Assets capitalized during the quarter | ₹87 cr |
| Capital work-in-progress | ₹512 cr underway; current capital work-in-progress about ₹500 cr |
| Cash on books (as of June 30) | ₹3,431 cr |
| Receivables (as of June 30) | ₹2,155 cr |
| Inventories (as of June 30) | ₹2,836 cr |
| Capacity utilization | 83%, with about 17% available; two new SEZ buildings under construction could add further headroom |
| Planned capex (without Kakinada) | ₹500–600 cr for new technologies and debottlenecking |
| Kakinada initial investment (if project proceeds) | ~₹1,000 cr |
| Raw material cost increases | Solvents up 30% to 50%, some even 100%; lithium up 100% to 200% |
| Energy cost increases | Coal from ₹6/kg to ₹8–8.5/kg; power from ₹6/unit to ₹8+/unit; generator power from ₹30–40/unit to ₹70–80/unit |
| Iodine price | $80/kg, up from $13/kg |
| Shipping cost (India to US, 40-ft container) | $11,000, roughly 3x the cost a year ago |
| Revenue growth over last 3 years | From ₹5,000 cr to ₹9,000 cr (profit after tax from ₹1,300 cr to ₹2,960 cr) |
| Profit after tax growth over last 3 years | From ₹1,300 cr to ₹2,960 cr (revenue from ₹5,000 cr to ₹9,000 cr) |
| Capex over last 3 years | ₹2,500 cr (invested, with revenue growing from ₹5,000 cr to ₹9,000 cr) |
| Top products concentration (FY22) | 60%, up from 49% |
| Top 5 customers concentration (FY22) | 54%, up from 34% |
| Import dependency (FY22) | 46%, up from 44% |
| US share of exports (FY22) | 44%, up from 24% |
| Europe share of exports (FY22) | 33%, down from 47% |